Cartesian Therapeutics (RNAC) Current Assets (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Current Assets for 12 consecutive years, with $122.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets fell 34.08% year-over-year to $122.0 million; the TTM figure through Mar 2026 stood at $122.0 million (down 34.08% YoY), while the FY2025 annual figure was $129.3 million, down 40.32% from the prior year.
• Current Assets declined to $122.0 million in Q1 2026 per RNAC's latest filing, from $129.3 million in the prior quarter.
• Across five years, Current Assets topped out at $229.1 million in Q3 2024 and bottomed at $89.9 million in Q3 2023.
• Historically, Current Assets has averaged $145.9 million across 5 years, with a median of $138.4 million in 2023.
• Annual changes were most pronounced in 2023 — Current Assets sank 43.72% — and 2024, when it jumped 154.97%.
• Cartesian Therapeutics' Current Assets stood at $148.1 million in 2022, then plunged by 38.75% to $90.7 million in 2023, then surged by 138.76% to $216.6 million in 2024, then slumped by 40.32% to $129.3 million in 2025, then retreated by 5.6% to $122.0 million in 2026.
• Business Quant data shows RNAC's Current Assets at $122.0 million in Q1 2026, $129.3 million in Q4 2025, and $147.3 million in Q3 2025.